IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
SIMILAR ACR20 RESPONSE SEEN REGARDLESS OF PRIOR ANTI-TNFα EXPOSURE1,2*†
PRIOR ANTI-TNFα
EXPOSURE
ACR20 RESPONSE BY PRIOR ANTI-TNFα EXPOSURE WAS A SUBGROUP ANALYSIS OF THE PRIMARY ENDPOINT (ACR20 RESPONSE AT WEEK 24) (NRI ANALYSIS)
DISCOVER 1: ACR20 RESPONSE RATES IN PATIENTS WITH NO PRIOR ANTI-TNFα EXPOSURE
ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.
DISCOVER 1: ACR20 RESPONSE RATES IN PATIENTS WITH PRIOR ANTI-TNFα EXPOSURE
ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.
NRI=nonresponder imputation; TNF=tumor necrosis factor.
*Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
†Patients with missing data were considered nonresponders.
References: 1. Data on File. Janssen Biotech, Inc. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.
